These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38504462)

  • 81. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.
    Bronckers IMGJ; Seyger MMB; West DP; Lara-Corrales I; Tollefson M; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Philipp S; Szalai Z; Vleugels RA; Holland K; Murphy R; Baselga E; Cordoro K; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Paller AS;
    JAMA Dermatol; 2017 Nov; 153(11):1147-1157. PubMed ID: 28903160
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Hepatotoxic potentials of methotrexate: Understanding the possible toxicological molecular mechanisms.
    Ezhilarasan D
    Toxicology; 2021 Jun; 458():152840. PubMed ID: 34175381
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Psoriasis-liver-methotrexate interactions.
    Arch Dermatol; 1973 Jul; 108(1):36-42. PubMed ID: 4716740
    [No Abstract]   [Full Text] [Related]  

  • 84. The treatment of psoriasis vulgaris: 1% topical methotrexate gel.
    Eskicirak B; Zemheri E; Cerkezoglu A
    Int J Dermatol; 2006 Aug; 45(8):965-9. PubMed ID: 16911386
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Partial reversal of androgenetic alopecia with methotrexate therapy for psoriasis.
    Famenini S; Wu JJ
    Cutis; 2013 Sep; 92(3):127-8. PubMed ID: 24153140
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis.
    Yamauchi PS; Lowe NJ
    Int J Dermatol; 2008 Feb; 47(2):202-4. PubMed ID: 18211500
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A clinical study to determine the efficacy and safety of 1% methotrexate/Azone (MAZ) gel applied topically once daily in patients with psoriasis vulgaris.
    Sutton L; Swinehart JM; Cato A; Kaplan AS
    Int J Dermatol; 2001 Jul; 40(7):464-7. PubMed ID: 11679005
    [No Abstract]   [Full Text] [Related]  

  • 88. Is concomitant use of methotrexate and oral retinoids dangerous? A review of the data regarding this combination.
    Searles AD; Lee AD; Feldman SR
    J Am Acad Dermatol; 2011 Apr; 64(4):791-3. PubMed ID: 21414504
    [No Abstract]   [Full Text] [Related]  

  • 89. Psoriasis, methotrexate, and cirrhosis.
    JAMA; 1970 Apr; 212(2):314-5. PubMed ID: 5467236
    [No Abstract]   [Full Text] [Related]  

  • 90. Galactose tolerance test and methotrexate-induced liver fibrosis and cirrhosis in patients with psoriasis.
    Lenler-Petersen P; Søgård H; Thestrup-Pedersen K; Zachariae H
    Acta Derm Venereol; 1982; 62(5):448-9. PubMed ID: 6183903
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Cirrhosis and methotrexate treatment of psoriasis.
    Auerbach R
    JAMA; 1969 Apr; 208(1):155. PubMed ID: 5818508
    [No Abstract]   [Full Text] [Related]  

  • 92. Guideline vs. practice in procollagen-3-aminopeptide monitoring.
    Parkins G; Wylie G
    Br J Dermatol; 2014 Dec; 171(6):1599-600. PubMed ID: 24930950
    [No Abstract]   [Full Text] [Related]  

  • 93. Recurrent recall of sunburn by methotrexate.
    Guzzo C; Kaidby K
    Photodermatol Photoimmunol Photomed; 1995 Apr; 11(2):55-6. PubMed ID: 8546984
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Methotrexate hepatotoxicity and the role of routine liver biopsy: a collective opinion.
    Sinclair RD; Rotstein H; Clemmens L; Prentice D; Rode J; Breen K
    Australas J Dermatol; 1995 Nov; 36(4):228-9. PubMed ID: 8593119
    [No Abstract]   [Full Text] [Related]  

  • 95. Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy.
    Rattanakaemakorn P; Pinyowiwat P; Iamsumang W; Chanprapaph K; Suchonwanit P
    Drug Des Devel Ther; 2021; 15():2299-2307. PubMed ID: 34093007
    [TBL] [Abstract][Full Text] [Related]  

  • 96. An anti-cancer drug used in psoriasis.
    Weinswig MH; Doerr DW
    J Am Pharm Assoc; 1967 May; 7(5):235. PubMed ID: 6043839
    [No Abstract]   [Full Text] [Related]  

  • 97. Safety of systemic therapies in the treatment of psoriasis with concomitant cirrhosis: a retrospective study.
    Blaszczak AM; Dunaway S; Ali Alikhan M; Kelly S; Levin D; Kaffenberger J
    Int J Dermatol; 2019 Nov; 58(11):e228-e229. PubMed ID: 31334835
    [No Abstract]   [Full Text] [Related]  

  • 98. Severe vertigo requiring hospitalization whilst taking low-dose oral methotrexate for psoriasis.
    Swale VJ; Sahota A
    Clin Exp Dermatol; 2005 May; 30(3):295-6. PubMed ID: 15807694
    [No Abstract]   [Full Text] [Related]  

  • 99. Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India.
    Sandhu K; Kaur I; Kumar B; Saraswat A
    J Dermatol; 2003 Jun; 30(6):458-63. PubMed ID: 12810993
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Managing risk of liver fibrosis in patients with psoriasis being considered for methotrexate.
    Campbell F; Laws P
    Br J Dermatol; 2024 Jul; 191(2):163. PubMed ID: 38504462
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.